Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · see citing works

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,602 · see citing works

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · see citing works

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542 · see citing works

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

Bono, J. S. D., Scher, H. I., Montgomery, B., Parker, C. C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. M. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,189 · see citing works

Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer

Cohen, S. J., Punt, C. J. A., Iannotti, N. O., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E. P., Miller, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8923 · Cited by 1,843 · see citing works

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations

Young, H. E., Baum, R. P., Cremerius, U., Herholz, K., Hoekstra, O. S., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,716 · see citing works

Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells

Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617 · see citing works

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,453 · see citing works

Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System

Riethdorf, S., Fritsche, H. A., Müller, V., Rau, T., Schindlbeck, C., Rack, B. K., Janni, W., Coith, C., Beck, K., Jänicke, F., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1695 · Cited by 1,342 · see citing works

Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer

Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., Doyle, G. V., Matera, J., Allard, W. J., Miller, M. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.140 · Cited by 1,134 · see citing works

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,123 · see citing works

Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

Hayes, D. F., Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Miller, M. C., Matera, J., Allard, W. J., Doyle, G. V., & Terstappen, L. W. M. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2821 · Cited by 1,032 · see citing works

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873 · see citing works

Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

Krebs, M., Sloane, R. A. S., Priest, L. J. C., Lancashire, L., Hou, J., Greystoke, A., Ward, T. H., Ferraldeschi, R., Hughes, A. M., Clack, G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7045 · Cited by 870 · see citing works

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

Danila, D. C., Heller, G., Gignac, G. A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E., Lilja, H. G., Schwartz, L. B., Larson, S. M., Fleisher, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1506 · Cited by 665 · see citing works

Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer

Sequist, L. V. D., Bell, D. W., Lynch, T. J., & Haber, D. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3585 · Cited by 617 · see citing works

Characterization of <i>ERG</i> , <i>AR</i> and <i>PTEN</i> Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

Attard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H. M., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3667 · Cited by 533 · see citing works

Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial

Riethdorf, S., Müller, V., Zhang, L., Rau, T., Loibl, S., Komor, M., Roller, M., Huober, J., Fehm, T. N., Schrader, I., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2042 · Cited by 490 · see citing works

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial

Fehm, T. N., Müller, V., Aktas, B., Janni, W., Schneeweiß, A., Stickeler, E., Lattrich, C., Löhberg, C. R., Solomayer, E. F., Rack, B. K., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1163-x · Cited by 354 · see citing works

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

Adams, C. W., Allison, D. E., Flagella, K. M., Presta, L. G., Clarke, J. B., Dybdal, N. O., McKeever, K., & Sliwkowski, M. X. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0058-x · Cited by 316 · see citing works

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting

Eberhard, D. A., Giaccone, G., & Johnson, B. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9858 · Cited by 300 · see citing works

Molecular Biomarker Analyses Using Circulating Tumor Cells

Punnoose, E. A., Atwal, S. K., Spoerke, J. M., Savage, H. M., Pandita, A., Yeh, R., Pirzkall, A., Fine, B. M., Amler, L. C., Chen, D. S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012517 · Cited by 294 · see citing works

Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

Bono, J. S. D., Attard, G., Adjei, A. A., Pollak, M., Fong, P. C. C., Haluska, P., Roberts, L., Melvin, C. L., Repollet, M., Chianese, D. A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0268 · Cited by 192 · see citing works

Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

Herbst, R. S., Davies, A. M., Natale, R. B., Dang, T. P., Schiller, J. H., Garland, L. L., Miller, V. A., Mendelson, D. S., den Abbeele, A. D. V., Melenevsky, Y. V., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0460 · Cited by 102 · see citing works

The partition method for poset-free families

Griggs, J. R., & Li, W. (2012) · Journal of Combinatorial Optimization · doi:10.1007/s10878-012-9476-9 · Cited by 47 · see citing works

Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations

Berghmans, T., Pasleau, F., Paesmans, M., Bonduelle, Y., Cadranel, J. L., Toth, I. C., Garcia, C., Giner, V., Holbrechts, S., Lafitte, J., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00190310 · Cited by 47 · see citing works

Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

Johnson, B. E., & Janne, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0629 · Cited by 40 · see citing works

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067 · see citing works

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · see citing works

Liquid Biopsies: Genotyping Circulating Tumor DNA

Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210 · see citing works

Liquid biopsy: monitoring cancer-genetics in the blood

Crowley, E. H., Nicolantonio, F. D., Loupakis, F., & Bardelli, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.110 · Cited by 1,821 · see citing works

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624 · see citing works

Circulating tumor cells: biology and clinical significance

Lin, D., Shen, L., Luo, M., Zhang, K., Li, J., Yang, Q., Zhu, F., Zhou, D., Zheng, S. S., Chen, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00817-8 · Cited by 1,017 · see citing works

Liquid biopsy: current technology and clinical applications

Nikanjam, M., Kato, S., & Kurzrock, R. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01351-y · Cited by 963 · see citing works

Circulating Tumor DNA as a Liquid Biopsy for Cancer

Heitzer, E., Ulz, P., & Geigl, J. B. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.222679 · Cited by 768 · see citing works

Molecular analysis of circulating tumour cells—biology and biomarkers

Krebs, M., Metcalf, R. L., Carter, L., Brady, G., Blackhall, F. H., & Dive, C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.253 · Cited by 620 · see citing works

The emerging role of cell-free DNA as a molecular marker for cancer management

Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2019) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2019.100087 · Cited by 566 · see citing works

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

Thress, K. S., Brant, R., Carr, T. H., Dearden, S. P., Jenkins, S. C., Brown, H. J., Hammett, T., Cantarini, M., & Barrett, J. C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.004 · Cited by 491 · see citing works

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

Aggarwal, C., Thompson, J. C., Black, T. A., Katz, S. I., Fan, R., Yee, S. S., Chien, A. L., Evans, T. L., Bauml, J. M., Alley, E. W., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4305 · Cited by 487 · see citing works

EMT, CTCs and CSCs in tumor relapse and drug-resistance

Mitra, A., Mishra, L., & Li, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4037 · Cited by 467 · see citing works

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

Tan, C., Gilligan, D., & Pacey, S. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00246-6 · Cited by 390 · see citing works

Lung Cancer Staging and Prognosis

Woodard, G. A., Jones, K. D., & Jablons, D. M. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40389-2_3 · Cited by 366 · see citing works

Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility

Ignatiadis, M., Lee, M., & Jeffrey, S. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1190 · Cited by 356 · see citing works

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Thompson, J. C., Yee, S. S., Troxel, A. B., Savitch, S. L., Fan, R., Balli, D., Lieberman, D. B., Morrissette, J. D., Evans, T. L., Bauml, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1231 · Cited by 325 · see citing works

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T. S. K., Novello, S., O'Byrne, K. J., Stahel, R. A., Peters, S., Felip, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu145 · Cited by 300 · see citing works

Clinical applications of the CellSearch platform in cancer patients

Riethdorf, S., O′Flaherty, L., Hille, C., & Pantel, K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.011 · Cited by 274 · see citing works

Plasma ctDNA Analysis for Detection of the EGFR  T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer

Jenkins, S., Yang, J. C.-H., Ramalingam, S. S., Yu, K., Patel, S., Weston, S., Hodge, R., Cantarini, M., Jänne, P. A., Mitsudomi, T., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.003 · Cited by 269 · see citing works

The kinome 'at large' in cancer

Fleuren, E. D. G., Zhang, L., Wu, J., & Daly, R. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2015.18 · Cited by 261 · see citing works

Circulating tumor cell isolation, culture, and downstream molecular analysis

Sharma, S., Zhuang, R., Long, M., Pavlović, M. D., Kang, Y., Ilyas, A., & Asghar, W. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.03.007 · Cited by 244 · see citing works

Targeted therapies for renal cell carcinoma

Posadas, E. M., Limvorasak, S., & Figlin, R. A. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.82 · Cited by 243 · see citing works

Size-based separation methods of circulating tumor cells

Hao, S.-J., Wan, Y., Xia, Y.-Q., Zou, X., & Zheng, S.-Y. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.002 · Cited by 239 · see citing works

Biomimetic Immuno‐Magnetosomes for High‐Performance Enrichment of Circulating Tumor Cells

Xiong, K., Wei, W., Jin, Y., Wang, S., Zhao, D., Wang, S., Gao, X., Qiao, C.-M., Yue, H., Ma, G., et al. (2016) · Advanced Materials · doi:10.1002/adma.201601643 · Cited by 230 · see citing works

Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?

Zhang, W., Xia, W., Lv, Z., Ni, C., Yin, X., & Yang, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000458736 · Cited by 229 · see citing works

Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities

Habli, Z. S., AlChamaa, W., Saab, R. H., Kadara, H. N., & Khraiche, M. L. (2020) · Cancers · doi:10.3390/cancers12071930 · Cited by 228 · see citing works

Platelet–Leukocyte Hybrid Membrane‐Coated Immunomagnetic Beads for Highly Efficient and Highly Specific Isolation of Circulating Tumor Cells

Rao, L., Meng, Q., Huang, Q., Wang, Z., Yu, G., Li, A., Ma, W., Zhang, N., Guo, S., Zhao, X., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201803531 · Cited by 226 · see citing works

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance

Zheng, D., Ye, X.-R., Zhang, M. Z., Sun, Y., Wang, J. Y., Ni, J., Zhang, H. P., Zhang, L., Luo, J., Zhang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep20913 · Cited by 224 · see citing works

Circulating tumor cells: clinical validity and utility

Cabel, L., Proudhon, C., Gortais, H., Loirat, D., Coussy, F., Pierga, J., & Bidard, F. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1105-2 · Cited by 220 · see citing works

Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model

Zhang, Z., Shiratsuchi, H., Lin, J., Chen, G., Reddy, R. M., Azizi, E., Fouladdel, S., Chang, A. C., Lin, L., Jiang, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2592 · Cited by 207 · see citing works

Clinical utility of circulating tumor cells: an update

Vasseur, A., Kiavué, N., Bidard, F., Pierga, J., & Cabel, L. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12869 · Cited by 201 · see citing works

Advanced liquid biopsy technologies for circulating biomarker detection

Soda, N., Rehm, B. H. A., Sonar, P. M., Nguyen, N., & Shiddiky, M. J. A. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01490j · Cited by 198 · see citing works

Technologies for label-free separation of circulating tumor cells: from historical foundations to recent developments

Jin, C., McFaul, S. M., Duffy, S. P., Deng, X., Tavassoli, P., Black, P. C., & Ma, H. (2013) · Lab on a Chip · doi:10.1039/c3lc50625h · Cited by 192 · see citing works

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

Spoerke, J. M., O'Brien, C. L., Huw, L. Y., Koeppen, H., Fridlyand, J., Brachmann, R. K., Haverty, P. M., Pandita, A., Mohan, S., Sampath, D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2347 · Cited by 181 · see citing works

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

Saura, C., Roda, D., Roselló, S., Oliveira, M., Macarulla, T. M., Fidalgo, J. A. P., Morales‐Barrera, R., Sanchis, J. M., Musib, L. C., Budha, N. R., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0512 · Cited by 173 · see citing works

Ultrahigh-throughput magnetic sorting of large blood volumes for epitope-agnostic isolation of circulating tumor cells

Mishra, A., Dubash, T. D., Jon, F., Jewett, M. K., Garre, S., Karabacak, M., Rabe, D. C., Mutlu, B. R., Walsh, J. R., Kapur, R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006388117 · Cited by 172 · see citing works

Enrichment, detection and clinical significance of circulating tumor cells

Arya, S. K., Lim, B., & Rahman, A. R. A. (2013) · Lab on a Chip · doi:10.1039/c3lc00009e · Cited by 167 · see citing works

Enrichment and single-cell analysis of circulating tumor cells

Song, Y., Tian, T., Shi, Y., Liu, W., Zou, Y. W., Khajvand, T., Wang, S., Zhu, Z., & Yang, C. J. (2016) · Chemical Science · doi:10.1039/c6sc04671a · Cited by 167 · see citing works

Molecular histology of lung cancer: From targets to treatments

Wood, S. L., Pernemalm, M., Crosbie, P. A. J., & Whetton, A. D. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.02.008 · Cited by 161 · see citing works

Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?

Ignatiadis, M., & Dawson, S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu480 · Cited by 158 · see citing works

Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer

Tjensvoll, K., Lapin, M., Buhl, T., Oltedal, S., Berry, K. S.-O., Gilje, B., Søreide, J. A., Javle, M. M., Nordgård, O., & Smaaland, R. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.11.012 · Cited by 155 · see citing works

Current approaches for avoiding the limitations of circulating tumor cells detection methods—implications for diagnosis and treatment of patients with solid tumors

Kowalik, A., Kowalewska, M., & Góźdź, S. S. (2017) · Translational research · doi:10.1016/j.trsl.2017.04.002 · Cited by 152 · see citing works

Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment

Marchetti, A., Grammastro, M. D., Felicioni, L., Malatesta, S., Filice, G., Centi, I., Pas, T. M. D., Santoro, A., Chella, A., Brandes, A. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103883 · Cited by 149 · see citing works

Three-color crystal digital PCR

Madic, J., Zocevic, A., Senlis, V., Fradet, E., Andre, B., Muller, S., Dangla, R., & Droniou, M. (2016) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2016.10.002 · Cited by 148 · see citing works

Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset

Agnoletto, C., Corrà, F., Minotti, L., Baldassari, F., Crudele, F., Cook, W. J. J., Leva, G. D., D’Adamo, P., Gasparini, P., & Volinia, S. (2019) · Cancers · doi:10.3390/cancers11040483 · Cited by 146 · see citing works

Liquid Biopsies, Novel Approaches and Future Directions

Armakolas, A., Kotsari, M., & Koskinas, J. S. (2023) · Cancers · doi:10.3390/cancers15051579 · Cited by 140 · see citing works

PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer

Wang, Y., Kim, T. H., Fouladdel, S., Zhang, Z., Soni, P., Qin, A., Zhao, L., Azizi, E., Lawrence, T. S., Ramnath, N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36096-7 · Cited by 138 · see citing works

A Radial Flow Microfluidic Device for Ultra‐High‐Throughput Affinity‐Based Isolation of Circulating Tumor Cells

Murlidhar, V., Zeinali, M., Grabauskiene, S., Ghannad‐Rezaie, M., Wicha, M. S., Simeone, D. M., Ramnath, N., Reddy, R. M., & Nagrath, S. (2014) · Small · doi:10.1002/smll.201400719 · Cited by 137 · see citing works

Circulating tumor cells as promising novel biomarkers in solid cancers

Lianidou, E. S., Strati, A. D., & Markou, A. N. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.896316 · Cited by 136 · see citing works

Liquid biopsy for lung cancer early detection

Santarpía, M., Liguori, A., D’Aveni, A., Karachaliou, N., González‐Cao, M., Daffinà, M. G., Lazzari, C., Altavilla, G., & Rosell, R. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.81 · Cited by 133 · see citing works

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Gray, J. E., Okamoto, I., Sriuranpong, V., Vansteenkiste, J., Imamura, F., Lee, J. S., Pang, Y., Cobo, M., Kasahara, K., Cheng, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1126 · Cited by 130 · see citing works

Prognostic Significance of Circulating Tumor Cells in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis

Huang, J., Wang, K., Xu, J., Huang, J., & Zhang, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078070 · Cited by 123 · see citing works

Microfluidic enrichment for the single cell analysis of circulating tumor cells

Yeo, T., Tan, S. J., Lim, C. L., Lau, D. P. X., Chua, Y. W., Krisna, S. S., Iyer, G., Tan, G. S., Lim, T. K. H., Tan, D. S. W., et al. (2016) · Scientific Reports · doi:10.1038/srep22076 · Cited by 123 · see citing works

Multivalent Aptamer Functionalized Ag2S Nanodots/Hybrid Cell Membrane‐Coated Magnetic Nanobioprobe for the Ultrasensitive Isolation and Detection of Circulating Tumor Cells

Ding, C., Zhang, C., Cheng, S., & Xian, Y. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909781 · Cited by 121 · see citing works

Lung Cancer Biomarkers

Hoseok, I., & Cho, J. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.07.003 · Cited by 119 · see citing works

Going with the Flow: From Circulating Tumor Cells to DNA

Bidard, F., Weigelt, B., & Reis-Filho, J. S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006305 · Cited by 118 · see citing works

Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens

Malekzadeh, P., Yossef, R., Cafri, G., Paria, B. C., Lowery, F. J., Jafferji, M. S., Good, M. L., Sachs, A., Copeland, A. R., Kim, S. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1874 · Cited by 118 · see citing works

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

Tamminga, M., de Wit, S., Hiltermann, T. J. N., Timens, W., Schuuring, E. M. D., Terstappen, L. W. M. M., & Groen, H. J. M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0649-2 · Cited by 116 · see citing works

The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC

Nygaard, A. D., Holdgaard, P. C., Spindler, K.-L. G., Pallisgaard, N., & Jakobsen, A. K. M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.705 · Cited by 115 · see citing works

Circulating Tumor DNA Outperforms Circulating Tumor Cells for KRAS Mutation Detection in Thoracic Malignancies

Freidin, M. B., Freydin, M., Leung, M., Montero, Á., Nicholson, A. G., & Lim, E. K. S. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.242453 · Cited by 110 · see citing works

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

Yanagita, M., Redig, A. J., Paweletz, C. P., Dahlberg, S. E., O’Connell, A., Feeney, N. B., Taibi, M., Boucher, D. H., Oxnard, G. R., Johnson, B. E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0909 · Cited by 108 · see citing works

The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer

Kapeleris, J., Kulasinghe, A., Warkiani, M. E., Vela, I., Kenny, L., O'Byrne, K. J., & Punyadeera, C. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00311 · Cited by 108 · see citing works

Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment

Muinelo‐Romay, L., Vieito, M., Abalo, A., Alonso‐Nocelo, M., Barón, F., Anido, U., Brozos-Vázquez, E., Vázquez, F., Aguín, S., Abal, M., et al. (2014) · Cancers · doi:10.3390/cancers6010153 · Cited by 107 · see citing works

Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring

Pérez-Callejo, D., Romero, A., Provencio, M., & Torrente, M. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.07 · Cited by 104 · see citing works

Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer

Malý, V., Malý, O., Kološtová, K., & Bobek, V. (2019) · In Vivo · doi:10.21873/invivo.11571 · Cited by 104 · see citing works

EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

Ke, E., & Wu, Y.-L. L. C. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.003 · Cited by 99 · see citing works

Aptamers Selected to Postoperative Lung Adenocarcinoma Detect Circulating Tumor Cells in Human Blood

Сергеевна, З. Г., Kolovskaya, O. S., Zamay, T. N., Glazyrin, Y. E., Krat, A. V., Zubkova, O. A., Spivak, E. A., Wehbe, M., Gargaun, A., Muharemagic, D., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.108 · Cited by 98 · see citing works

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Fariñas, S. C., Lewintre, E. J., Herreros‐Pomares, A., & Camps, C. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.02 · Cited by 95 · see citing works

Liquid biomarkers in melanoma: detection and discovery

Lim, S. Y., Lee, J., Diefenbach, R. J., Kefford, R. F., & Rizos, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0757-5 · Cited by 95 · see citing works

Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)

Lim, M., Kim, C., Sunkara, V., Kim, M., & Cho, Y. (2018) · Micromachines · doi:10.3390/mi9030100 · Cited by 95 · see citing works

EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer

Lindsay, C. R., Blackhall, F. H., Carmel, A., Fernández‐Gutiérrez, F., Gazzaniga, P., Groen, H. J. M., Hiltermann, T. J. N., Krebs, M., Loges, S., López‐López, R., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.019 · Cited by 94 · see citing works

A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance

Wang, W., Song, Z., & Zhang, Y. (2016) · Cancer Medicine · doi:10.1002/cam4.978 · Cited by 93 · see citing works

Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer

Tang, Y., Qiao, G., Xu, E., Xuan, Y., Liao, M., & Yin, G. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s142149 · Cited by 93 · see citing works

Size-Based Differentiation of Cancer and Normal Cells by a Particle Size Analyzer Assisted by a Cell-Recognition PC Software

Shashni, B., Ariyasu, S., Takeda, R., Suzuki, T., Shiina, S., Akimoto, K., Maeda, T., Aikawa, N., Abe, R., Osaki, T., et al. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00776 · Cited by 93 · see citing works

The Role of CTCs as Tumor Biomarkers

Lianidou, E. S., Markou, A. N., & Strati, A. D. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7215-0_21 · Cited by 92 · see citing works

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer

Ai, B., Liu, H., Huang, Y., & Peng, P. (2016) · Oncotarget · doi:10.18632/oncotarget.10069 · Cited by 92 · see citing works

Molecular Biomarkers of Cancer Stem/Progenitor Cells Associated with Progression, Metastases, and Treatment Resistance of Aggressive Cancers

Mimeault, M., & Batra, S. K. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0785 · Cited by 91 · see citing works

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups

Lindsay, C. R., Faugeroux, V., Michiels, S., Pailler, E., Facchinetti, F., Ou, D., Bluthgen, M. V., Pannet, C., Ngo‐Camus, M., Bescher, G., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx156 · Cited by 90 · see citing works

Current status of research and treatment for non-small cell lung cancer in never-smoking females

Saito, S., Espinoza-Mercado, F., Liu, H., Sata, N., Cui, X., & Soukiasian, H. J. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323580 · Cited by 87 · see citing works

Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq

Bratman, S. V., Newman, A. M., Alizadeh, A. A., & Diehn, M. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1019476 · Cited by 87 · see citing works

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

Sun, W., Yuan, X., Tian, Y., Wu, H. K., Xu, H., Hu, G., & Wu, K. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0193-6 · Cited by 86 · see citing works

Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non‐small‐cell lung cancer

Zhang, Z., Xiao, Y., Zhao, J., Chen, M., Xu, Y., Zhong, W., Xing, J., & Wang, M. (2015) · Respirology · doi:10.1111/resp.12696 · Cited by 85 · see citing works

The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring

Bracht, J. W. P., Mayo‐de‐las‐Casas, C., Berenguer, J., Karachaliou, N., & Rosell, R. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0720-z · Cited by 84 · see citing works

Applications of DNA-Based Liquid Biopsy for Central Nervous System Neoplasms

Wang, J., & Bettegowda, C. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.08.007 · Cited by 84 · see citing works

Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients

Vallée, A., Marcq, M., Bizieux, A., Kouri, C. E., Lacroix, H., Bennouna, J., Douillard, J., & Denis, M. G. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.014 · Cited by 84 · see citing works

Role of circulating-tumor DNA analysis in non-small cell lung cancer

Jiang, T., Ren, S., & Zhou, C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.09.013 · Cited by 82 · see citing works

Cell-free nucleic acid patterns in disease prediction and monitoring—hype or hope?

Crigna, A. T., Samec, M., Koklesová, L., Líšková, A., Giordano, F. A., Kubatka, P., & Golubnitschaja, O. (2020) · The EPMA Journal · doi:10.1007/s13167-020-00226-x · Cited by 79 · see citing works

Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System

Truini, A., Alama, A., Bello, M. G. D., Coco, S., Vanni, I., Rijavec, E., Genova, C., Barletta, G., Biello, F., & Grossi, F. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00242 · Cited by 78 · see citing works

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer

Yang, X., Zhuo, M., Ye, X., Bai, H., Wang, Z., Sun, Y., Zhao, J., An, T., Duan, J., Wu, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8021 · Cited by 78 · see citing works

Circulating Tumor Cells as Predictive and Prognostic Biomarkers in Solid Tumors

Capuozzo, M., Ferrara, F., Santorsola, M., Zovi, A., & Ottaiano, A. (2023) · Cells · doi:10.3390/cells12222590 · Cited by 74 · see citing works

Liquid biopsy into the clinics: Current evidence and future perspectives

Boukovala, M. A., Westphalen, C. B., & Probst, V. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100146 · Cited by 74 · see citing works

Plasticity of tumor cell invasion: governance by growth factors and cytokines

Odenthal, J., Takes, R. P., & Friedl, P. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw098 · Cited by 74 · see citing works

Blood-based tumor biomarkers in lung cancer for detection and treatment

Mamdani, H. M., Ahmed, S. S., Armstrong, S. A., Mok, T. S. K., & Jalal, S. I. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.09.03 · Cited by 74 · see citing works

Clinical indications for, and the future of, circulating tumor cells

Moon, D. H., Lindsay, D. P., Hong, S., & Wang, A. Z. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.002 · Cited by 71 · see citing works

Quantification of Rare Circulating Tumor Cells in Non-Small Cell Lung Cancer by Ligand-Targeted PCR

Lou, J., Ben, S., Yang, G., Liang, X., Wang, X., Ni, S., & Han, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080458 · Cited by 70 · see citing works

Radiomics and liquid biopsy in oncology: the holons of systems medicine

Neri, E., Re, M. D., Paiar, F., Erba, P. A., Cocuzza, P., Regge, D., & Danesi, R. (2018) · Insights into Imaging · doi:10.1007/s13244-018-0657-7 · Cited by 70 · see citing works

Role of circulating tumor cells in future diagnosis and therapy of cancer

Potdar, P. D., & Lotey, N. (2015) · Journal of Cancer Metastasis and Treatment · doi:10.4103/2394-4722.158803 · Cited by 69 · see citing works

Circulating Tumor Cells in Lung Cancer

Young, R., Pailler, E., Billiot, F., Drusch, F., Barthelemy, A., Oulhen, M., Besse, B., Soria, J., Farace, F., & Vielh, P. R. (2012) · Acta Cytologica · doi:10.1159/000345182 · Cited by 69 · see citing works

Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors

Coakley, M. F., García-Murillas, I., & Turner, N. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0152 · Cited by 68 · see citing works

Abstract PR-3: Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.

Punnoose, E. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-pr-3

Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer.

Isobe, K., Hata, Y., Kobayashi, K., Hirota, N., Sato, K., Sano, G., Sugino, K., Sakamoto, S., Takai, Y., Shibuya, K., et al. (2012) · PubMed · Cited by 59 · see citing works

Detection of circulating tumor cells and its correlation with clinical outcome in non-small cell lung cancer.

Tariki, M. S., Romero, J. V., Abdallah, E. A., Ocea, L. M. M., Mingues, N. B., Gasparini, J. L., Silva, V. A., Fanelli, M. F., Dettino, A. A., Pereira, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.e22020

Circulating Tumor DNA and [18F]FDG-PET for Early Response Assessment in Patients with Advanced NSCLC

Ryssel, H., Ahlborn, L., Dejanovic, D., Keller, S. H., Pøhl, M., Østrup, O., Loft, A., Fischer, B. M., Langer, S., Kjaer, A., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15030247 · Cited by 3 · see citing works

The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer

Zhou, J., Dong, F., Cui, F., Xu, R., & Tang, X. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3269-x · Cited by 38 · see citing works